Your AI-Trained Oncology Knowledge Connection!
Independent variables, such as the burden of disease prior to treatment, molecular prognosis, sensitivity to chemotherapy, sensitivity to endocrine therapy, and sensitivity to other treatments could be effective in predicting risk of recurrence in patients with breast cancer.
Data from the POLLUX and CASTOR trials both found higher sustained MRD-negativity rates for daratumumab combination regimens compared with the standard-of-care treatments.
The trial investigated the association of bone metastatic burden and metastasis location with overall survival and failure-free survival, suggesting the potential for these data to predict survival benefits.
Based on results of the phase 3 TIVO-3 trial in patients who have previously received at least 2 lines of therapy for renal cell carcinoma, the FDA granted approval to tivozanib for use in this patient population.
The liquid biopsy assay RaDaR has been given a breakthrough device designation for use in the detection of minimal residual disease in early-stage cancers.
Kevin Kalinsky, MD, MS, discussed a number of antibody-drug conjugates, detailing the prevailing data and potential trials that may change the treatment paradigm for patients with breast cancer.
Data in The Lancet Oncology confirmed the standard of care as the optimal dosage to treat patients with indolent non-Hodgkin lymphoma.
Pal discussed the emergence of cabozantinib as a treatment option for patients with renal cell carcinoma and touched on future research around the drug.
Mandar Aras, MD, PhD, discussed the management and prevention of cardiotoxicity in patients receiving systemic therapy for breast cancer at the 38th Annual Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC.
Data from Radiology found early positive results regarding the treatment of intermediate-risk prostate cancer with MRI-guided focused ultrasound ablation.
Novartis’ investigational interleukin-1β inhibitor canakinumab plus docetaxel failed to show a survival benefit in patients with previously treated locally advanced or metastatic non–small cell lung cancer, but other trials examining its efficacy remain ongoing.
During Colorectal Cancer Awareness month, CancerNetwork® sat down with Dorothy Dulko, PhD, to discuss social determinants of cancer.
The medical oncologist at Memorial Sloan Kettering Cancer Center discussed areas of research in renal cell carcinoma that he thinks should be further explored.
Susan B. Kesmodel, MD, FACS, of the University of Miami, describes 3 methods by which breast surgical oncologists can strategize to reduce the incidence of lymphedema in patients undergoing surgery for breast tumors.
Take a look back at some of the important news and notes from last week in the world of oncology, featuring news about prostate cancer, breast cancer, lung cancer, and more.
As part of an industry-wide assessment of indications based on accelerated approval, Roche in consultation with the FDA has decided to withdraw the indication for atezolizumab in patients with urothelial carcinoma following platinum-based chemotherapy.
“Neoadjuvant endocrine therapy trials are feasible with relatively low toxicity,” Kelly K. Hunt, MD, FACS, FSSO, said during the 38th Annual Miami Breast Cancer Conference®.
Pal detailed the phase 2 trial of lenvatinib at 2 starting doses plus everolimus to treat patients with renal cell carcinoma.
Adam Brufsky, MD, PhD, presented data investigating immunotherapeutic options in the neoadjuvant setting for patients with triple-negative breast cancer.
The medical oncologist at Memorial Sloan Kettering Cancer Center explained how this trial of MK-6482 plus lenvatinib versus cabozantinib in patients with advanced clear cell renal cell carcinoma could possibly improve the standard of care in this setting.
Sara A. Hurvitz, MD, FACP, of the University of California, Los Angeles, discussed a number of emerging novel therapies with the potential to treat patients with HER2-positive metastatic breast cancer in the third-line setting.
Allowing for the use of antiemetic prophylaxis and anti-diarrheal medication in the phase 3 KX-ORAX-001 study reduced study drug-related gastrointestinal adverse events.
Phyllis Morgan, PhD, sat down with CancerNetwork® to discuss health disparities during Colorectal Cancer Awareness Month.
Data from the phase 2 ZUMA-5 trial supported the approval of axicabtagene ciloleucel, a chimeric antigen receptor T-cell therapy, as a treatment for patients with follicular lymphoma in the third-line setting.
At the Miami Breast Cancer Conference, Debu Tripathy, MD, reviewed adaptive therapy for the adjuvant treatment of patients with HER2-positive, early-stage breast cancer.
Data focusing on patients seeking breast surgical procedures determined that broad skill sets are valuable for general surgeons practicing in rural areas, as breast surgeries only represented a small proportion of total surgical procedures conducted.
The addition of neratinib to capecitabine improved progression-free survival and central nervous system outcomes in patients with HER2-positive metastatic breast cancer with central nervous system disease.
More patients with early-stage estrogen receptor–positive breast cancer with high recurrence scores received chemotherapy following radiation in a single-institution study, and this resulted in a low recurrence rate across all patients examined.
The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.
The medical oncologist at Memorial Sloan Kettering Cancer Center highlighted what clinicians treating patients with advanced ccRCC should understand about this trial in progress.
